Skip to menu Skip to content Skip to footer
Emeritus Professor Michael Pender
Emeritus Professor

Michael Pender

Email: 
Phone: 
+61 7 336 55132

Overview

Background

Emeritus Professor Michael Pender graduated from The University of Queensland in 1974 with First Class Honours in Medicine and a University Medal. Over the next six years he trained as a physician and neurologist at the Royal Prince Alfred Hospital and St Vincent's Hospital, Sydney, and became a Fellow of the Royal Australasian College of Physicians (FRACP) in 1981. During his specialist clinical training he developed a keen interest in multiple sclerosis which he has continued since then. After completing his clinical training in neurology, he was a research scholar in the field of multiple sclerosis at the Institute of Neurology, Queen Square, London, and was awarded a PhD from the University of London and Queen Square Prize for Research in 1983. From 1984 to 1986 he continued this research as a Research Fellow at the John Curtin School of Medical Research, Australian National University, Canberra. In 1987 he was appointed Senior Lecturer in the Department of Medicine, The University of Queensland, at the Royal Brisbane Hospital. In 1989 he was awarded a Doctorate of Medicine from The University of Queensland for his research in the field of multiple sclerosis and was promoted to Reader in Medicine. In 1995 he was promoted to Professor of Medicine (Personal Chair), The University of Queensland, which he held until his retirement in 2021. His main clinical and research interest is multiple sclerosis. He also held the positions of: Consultant Neurologist, Royal Brisbane and Women's Hospital, 1987–2021; Director of Neurology, Royal Brisbane and Women's Hospital, 1992–2005: Director of the Neuroimmunology Research Centre, The University of Queensland, 1991–2007; Director of the Multiple Sclerosis Research Centre, The University of Queensland, 2009–2014; and Clinical Fellow, QIMR Berghofer Medical Research Institute, 2017–2021. In 1996, with the support of the Multiple Sclerosis Society of Queensland, he established a Multiple Sclerosis Clinic at the Royal Brisbane and Women's Hospital. In 2006 he was awarded the Multiple Sclerosis Australia Prize for Multiple Sclerosis Research - "For outstanding commitment and dedication to research into the cause and cure of Multiple Sclerosis in Australia". In 2011 he received the John H Tyrer Prize in Internal Medicine, The University of Queensland, for research in the field of Internal Medicine. He was the Sir Raphael Cilento Orator of the Royal Australasian College of Medical Administrators for 2009 and the W Ian McDonald Lecturer of the Australian and New Zealand Association of Neurologists for 2014. In 2019 he received the John Studdy Award from Multiple Sclerosis Australia for "lifelong commitment and service to research to identify the cause of and potential cure for Multiple Sclerosis". In 2024 he was appointed a Member of the Order of Australia for significant service to medicine, particularly neurology and multiple sclerosis research, and to tertiary education. Major research achievements include: the discovery of apoptosis of autoreactive T cells in the central nervous system as a fundamental mechanism of recovery from autoimmune attack (Journal of the Neurological Sciences 1991, Journal of Autoimmunity 1992, European Journal of Immunology 1994); formulation of a novel hypothesis (The Lancet 1998) proposing a failure of this mechanism in multiple sclerosis; and the further development of this hypothesis into a new paradigm (Trends in Immunology 2003) for the cause of human chronic autoimmune diseases based on infection of autoreactive B cells with the Epstein–Barr virus (EBV), some of the predictions of which have already been verified in multiple sclerosis, rheumatoid arthritis and Sjögren’s syndrome. His EBV hypothesis led to the first clinical trial of EBV-specific T cell therapy in multiple sclerosis (JCI Insight 2018), a trial in which he was a principal investigator.

Group page: https://medicine-program.uq.edu.au/multiple-sclerosis-research-group

Availability

Emeritus Professor Michael Pender is:
Not available for supervision

Fields of research

Qualifications

  • Bachelor (Honours) of Medicine Surgery, The University of Queensland
  • Doctor of Philosophy, University College London
  • Doctoral Diploma of Medicine, The University of Queensland
  • Royal Australasian College of Physicians, Royal Australasian College of Physicians

Works

Search Professor Michael Pender’s works on UQ eSpace

267 works between 1982 and 2024

21 - 40 of 267 works

2018

Journal Article

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

Pender, Michael P., Csurhes, Peter A., Smith, Corey, Douglas, Nanette L., Neller, Michelle A., Matthews, Katherine K., Beagley, Leone, Rehan, Sweera, Crooks, Pauline, Hopkins, Tracey J., Blum, Stefan, Green, Kerryn A., Ioannides, Zara A., Swayne, Andrew, Aftab, Blake T., Hooper, Kaye D., Burrows, Scott R., Thompson, Kate M., Coulthard, Alan and Khanna, Rajiv (2018). Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis. JCI Insight, 3 (22) e124714. doi: 10.1172/jci.insight.124714

Epstein-Barr virus–specific T cell therapy for progressive multiple sclerosis

2018

Journal Article

PLP1 mutations in patients with multiple sclerosis: identification of a new mutation and potential pathogenicity of the mutations

Cloake, Nancy, Yan, Jun, Aminian, Atefeh, Pender, Michael and Greer, Judith (2018). PLP1 mutations in patients with multiple sclerosis: identification of a new mutation and potential pathogenicity of the mutations. Journal of Clinical Medicine, 7 (10) 342, 342. doi: 10.3390/jcm7100342

PLP1 mutations in patients with multiple sclerosis: identification of a new mutation and potential pathogenicity of the mutations

2018

Journal Article

Increased constitutive activation of NF-κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis

Yan, Jun, Winterford, Clay M., Catts, Vibeke S., Pat, Betty K., Pender, Michael P., McCombe, Pamela A. and Greer, Judith M. (2018). Increased constitutive activation of NF-κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis. Journal of Neuroimmunology, 320, 111-116. doi: 10.1016/j.jneuroim.2018.04.002

Increased constitutive activation of NF-κB p65 (RelA) in peripheral blood cells of patients with progressive multiple sclerosis

2018

Journal Article

Onset symptoms, tobacco smoking, and progressive-onset phenotype are associated with a delayed onset of multiple sclerosis, and marijuana use with an earlier onset

Tao, Chunrong, Simpson, Steve, Taylor, Bruce V., Blizzard, Leigh, Lucas, Robyn M., Ponsonby, Anne-Louise, Broadley, Simon, van der Mei, Ingrid, AusLong/Ausimmune Investigators Group, Dear, Keith, Dwyer, Terry, Kilpatrick, Trevor, Williams, David, Lechner-Scott, Jeanette, Shaw, Cameron, Chapman, Caron, Coulthard, Alan, Pender, Michael P. and Valery, Patricia (2018). Onset symptoms, tobacco smoking, and progressive-onset phenotype are associated with a delayed onset of multiple sclerosis, and marijuana use with an earlier onset. Frontiers in Neurology, 9 (JUN) 418. doi: 10.3389/fneur.2018.00418

Onset symptoms, tobacco smoking, and progressive-onset phenotype are associated with a delayed onset of multiple sclerosis, and marijuana use with an earlier onset

2018

Conference Publication

Antibodies specific for myelin proteolipid protein can inhibit remyelination in vivo

Bagert, Bridget, Greer, Judith, Savage, Hannah, Beasley, Shannon, Juba, Gracy and Pender, Michael (2018). Antibodies specific for myelin proteolipid protein can inhibit remyelination in vivo. AAN 70th Annual Meeting, Los Angeles, CA United States, 21-27 April 2018. Philadelphia, PA United States: Wolters Kluwer. doi: 10.1212/wnl.90.15_supplement.s52.001

Antibodies specific for myelin proteolipid protein can inhibit remyelination in vivo

2018

Journal Article

Reported changes in dietary behavior following a first clinical diagnosis of central nervous system demyelination

Russell, Rebecca D., Lucas, Robyn M., Brennan, Vanessa, Sherriff, Jill L., Begley, Andrea, Black, Lucinda J., The Ausimmune Investigator Group, Chapman, Caron, Coulthard, Alan, Dear, Keith, Dwyer, Terry, Kilpatrick, Trevor, Lucas, Robyn, McMichael, Tony, Pender, Michael P., Ponsonby, Anne-Louise, Taylor, Bruce, Valery, Patricia, van der Mei, Ingrid and Williams, David (2018). Reported changes in dietary behavior following a first clinical diagnosis of central nervous system demyelination. Frontiers in Neurology, 9 (MAR) 161. doi: 10.3389/fneur.2018.00161

Reported changes in dietary behavior following a first clinical diagnosis of central nervous system demyelination

2018

Journal Article

Sun exposure across the life course significantly modulates early multiple sclerosis clinical course

Simpson, Steve, Van Der Mei, Ingrid, Lucas, Robyn M., Ponsonby, Anne-Louise, Broadley, Simon, Blizzard, Leigh, Taylor, Bruce, Dear, Keith, Dwyer, Terry, Taylor, Bruce V., Kilpatrick, Trevor, Williams, David, Lechner-Scott, Jeanette, Shaw, Cameron, Chapman, Caron, Coulthard, Alan, Pender, Michael P. and Valery, Patricia (2018). Sun exposure across the life course significantly modulates early multiple sclerosis clinical course. Frontiers in Neurology, 9 (FEB) 16. doi: 10.3389/fneur.2018.00016

Sun exposure across the life course significantly modulates early multiple sclerosis clinical course

2018

Conference Publication

Antibodies specific for myelin proteolipid protein can inhibit remyelination in vivo

Bagert, Bridget, Greer, Judith, Savage, Hannah, Beasley, Shannon, Juba, Gracy and Pender, Michael (2018). Antibodies specific for myelin proteolipid protein can inhibit remyelination in vivo. 70th Annual Meeting of the American Academy of Neurology (AAN), Los Angeles, California, 21-27 April 2018. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

Antibodies specific for myelin proteolipid protein can inhibit remyelination in vivo

2017

Journal Article

Incidence and prevalence of NMOSD in Australia and New Zealand

Bukhari, Wajih, Prain, Kerri M., Waters, Patrick, Woodhall, Mark, O'Gorman, Cullen M., Clarke, Laura, Silvestrini, Roger A., Bundell, Christine S., Abernethy, David, Bhuta, Sandeep, Blum, Stefan, Boggild, Mike, Boundy, Karyn, Brew, Bruce J., Brown, Matthew, Brownlee, Wallace J., Butzkueven, Helmut, Carroll, William M., Chen, Celia, Coulthard, Alan, Dale, Russell C., Das, Chandi, Dear, Keith, Fabis-Pedrini, Marzena J., Fulcher, David, Gillis, David, Hawke, Simon, Heard, Robert, Henderson, Andrew P. D. ... Broadley, Simon A. (2017). Incidence and prevalence of NMOSD in Australia and New Zealand. Journal of Neurology Neurosurgery and Psychiatry, 88 (8), 632-638. doi: 10.1136/jnnp-2016-314839

Incidence and prevalence of NMOSD in Australia and New Zealand

2017

Journal Article

Stressful life events and the risk of initial central nervous system demyelination

Saul, Alice, Ponsonby, Anne-Louise, Lucas, Robyn M., Taylor, Bruce V., Simpson, Steve, Jr., Valery, Patricia, Dwyer, Terence, Kilpatrick, Trevor J., Pender, Michael P. and van der Mei, Ingrid A. F. (2017). Stressful life events and the risk of initial central nervous system demyelination. Multiple Sclerosis Journal, 23 (7), 1000-1007. doi: 10.1177/1352458516667566

Stressful life events and the risk of initial central nervous system demyelination

2017

Journal Article

Reactivity to novel autoantigens in patients with coexisting central nervous system demyelinating disease and autoimmune thyroid disease

Greer, Judith M., Broadley, Simon and Pender, Michael P. (2017). Reactivity to novel autoantigens in patients with coexisting central nervous system demyelinating disease and autoimmune thyroid disease. Frontiers in Immunology, 8 (514) 514, 514. doi: 10.3389/fimmu.2017.00514

Reactivity to novel autoantigens in patients with coexisting central nervous system demyelinating disease and autoimmune thyroid disease

2017

Journal Article

Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis

Pender, Michael P., Csurhes, Peter A., Burrows, Jacqueline M. and Burrows, Scott R. (2017). Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis. Clinical and Translational Immunology, 6 (1) e126, 1-17. doi: 10.1038/cti.2016.87

Defective T-cell control of Epstein-Barr virus infection in multiple sclerosis

2017

Conference Publication

Symptomatic and objective clinical improvement in progressive multiple sclerosis patients treated with autologous Epstein-Barr virus-specific T cell therapy: interim results of a phase I trial

Pender, Michael, Csurhes, Peter, Smith, Corey, Douglas, Nanette, Neller, Michelle, Beagley, Leone, Rehan, Sweera, Hopkins, Tracey, Thompson, Kate, Blum, Stefan, Green, Kerryn, Ioannides, Zara, Coulthard, Alan, Hooper, Kaye, Burrows, Scott and Khanna, Rajiv (2017). Symptomatic and objective clinical improvement in progressive multiple sclerosis patients treated with autologous Epstein-Barr virus-specific T cell therapy: interim results of a phase I trial. 69th Annual Meeting of the American Academy of Neurology (AAN), Boston, Massachusetts, 22-28 April 2017. Philadelphia, PA, United States: Lippincott Williams & Wilkins.

Symptomatic and objective clinical improvement in progressive multiple sclerosis patients treated with autologous Epstein-Barr virus-specific T cell therapy: interim results of a phase I trial

2017

Conference Publication

Safety and clinical improvement in a phase I trial of autologous Epstein-Barr virus-specific T-cell therapy in patients with progressive multiple sclerosis

Pender, M. P., Csurhes, P. A., Smith, C., Douglas, N. L., Neller, M. A., Beagley, L., Rehan, S., Hopkins, T. J., Thompson, K. M., Blum, S., Green, K. A., Ioannides, Z. A., Coulthard, A., Hooper, K. D., Burrows, S. R. and Khanna, R. (2017). Safety and clinical improvement in a phase I trial of autologous Epstein-Barr virus-specific T-cell therapy in patients with progressive multiple sclerosis. 7th Joint European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS), Paris, France, 25-28 October 2017. London, United Kingdom: Sage Publications.

Safety and clinical improvement in a phase I trial of autologous Epstein-Barr virus-specific T-cell therapy in patients with progressive multiple sclerosis

2016

Journal Article

Population attributable fractions and joint effects of key risk factors for multiple sclerosis

Van Der Mei, I. A. F., Lucas, R. M., Taylor, B. V., Valery, P. C., Dwyer, T., Kilpatrick, T. J., Pender, M. P., Williams, D., Chapman, C., Otahal, P. and Ponsonby, A. L. (2016). Population attributable fractions and joint effects of key risk factors for multiple sclerosis. Multiple Sclerosis, 22 (4), 461-469. doi: 10.1177/1352458515594040

Population attributable fractions and joint effects of key risk factors for multiple sclerosis

2016

Conference Publication

Functional effects of antibodies specific for myelin proteolipid protein in multiple sclerosis

Greer, J. M., Muller, D. M., Beasley, S. J., Trifilieff, E. and Pender, M. P. (2016). Functional effects of antibodies specific for myelin proteolipid protein in multiple sclerosis. ICI 2016 International Congress of Immunology, Melbourne, Australia, 21–26 August 2016. Weinheim, Germany: Wiley.

Functional effects of antibodies specific for myelin proteolipid protein in multiple sclerosis

2015

Conference Publication

Impaired T cell control of Epstein-Barr virus infection in multiple sclerosis

Pender, Michael, Csurhes, Peter and Burrows, Scott (2015). Impaired T cell control of Epstein-Barr virus infection in multiple sclerosis. MS Research Australia Progress in MS Research Conference, Melbourne, Australia, Oct 29-30, 2015. London, EC1Y 1SP United Kingdom: SAGE PUBLICATIONS LTD. doi: 10.1177/1352458515616527

Impaired T cell control of Epstein-Barr virus infection in multiple sclerosis

2014

Journal Article

Epstein–Barr virus and multiple sclerosis: potential opportunities for immunotherapy

Pender, Michael P. and Burrows, Scott R. (2014). Epstein–Barr virus and multiple sclerosis: potential opportunities for immunotherapy. Clinical and Translational Immunology, 3 (10) e27, e27. doi: 10.1038/cti.2014.25

Epstein–Barr virus and multiple sclerosis: potential opportunities for immunotherapy

2014

Journal Article

Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia

Jones, Amanda L., Mowry, Bryan J., McLean, Duncan E., Mantzioris, Basil X., Pender, Michael P. and Greer, Judith M. (2014). Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia. Journal of Neuroimmunology, 269 (1-2), 68-75. doi: 10.1016/j.jneuroim.2014.02.008

Elevated levels of autoantibodies targeting the M1 muscarinic acetylcholine receptor and neurofilament medium in sera from subgroups of patients with schizophrenia

2014

Journal Article

Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis

Pender, Michael P., Csurhes, Peter A., Smith, Corey, Beagley, Leone, Hooper, Kaye D., Raj, Meenakshi, Coulthard, Alan, Burrows, Scott R. and Khanna, Rajiv (2014). Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis. Multiple Sclerosis Journal, 20 (11), 1541-1544. doi: 10.1177/1352458514521888

Epstein-Barr virus-specific adoptive immunotherapy for progressive multiple sclerosis

Funding

Past funding

  • 2018 - 2020
    Epstein-Barr virus infection in multiple sclerosis
    Atara Biopharmaceuticals, Inc.
    Open grant
  • 2018 - 2020
    Follow-up of patients with progressive multiple sclerosis treated with autologous Epstein Barr virus-specific T cell therapy
    Multiple Sclerosis Society of Queensland
    Open grant
  • 2016 - 2017
    Phase 1 trial of autologous Epstein-Barr virus-specific T cell therapy as treatment of progressive multiple sclerosis
    Queensland Institute of Medical Research
    Open grant
  • 2014 - 2015
    Do antibodies against myelin proteolipid protein play a role in multiple sclerosis?
    Ochsner Clinic Foundation
    Open grant
  • 2014 - 2017
    Investigation of the functional role of antibodies against myelin proteolipid protein in multiple sclerosis
    NHMRC Project Grant
    Open grant
  • 2013 - 2015
    CD8 T cell control of the Epstein-Barr virus in multiple sclerosis
    Multiple Sclerosis Research Australia
    Open grant
  • 2012 - 2014
    Understanding the interplay between the spectrum of glial and neuronal autoantibodies and clinical outcome in multiple sclerosis
    Multiple Sclerosis Research Australia
    Open grant
  • 2011 - 2013
    NFKBIA mutations as a mechanism leading to constitutive activation of NF-kB in patients with primary progressive MS
    Multiple Sclerosis Research Australia
    Open grant
  • 2010 - 2012
    Molecular interactions underpinning lesion localization in multiple sclerosis.
    Multiple Sclerosis Research Australia
    Open grant
  • 2010 - 2012
    The role of immunity to Epstein-Barr virus in the development of multiple sclerosis
    Multiple Sclerosis Research Australia
    Open grant
  • 2009 - 2012
    Mayne Bequest Fund Research Support Award: Research on multiple sclerosis
    Mayne Bequest Fund
    Open grant
  • 2009 - 2011
    Development of specific immunomodulatory agents for Multiple Sclerosis affecting the brainstem and cerebellum
    Multiple Sclerosis Research Australia
    Open grant
  • 2007 - 2009
    Mechanisms leading to constitutive activation of the transcription factor NF-kB in progressive multiple sclerosis
    Multiple Sclerosis Research Australia
    Open grant
  • 2005 - 2008
    Investigations In Multiple Sclerosis Patients With Coexistent Autoimmune Thyroid Disease
    NHMRC Project Grant
    Open grant
  • 2005 - 2007
    Studies on the functional role of antibodies in multiple sclerosis
    Multiple Sclerosis Research Australia
    Open grant
  • 2005 - 2006
    The Study of T-Cell responses to Epstein-Barr virus in Multiple Sclerosis
    Multiple Sclerosis Research Australia
    Open grant
  • 2004 - 2006
    The Australian Multi-Centre Study of Environment and Immune Function (AusImmune Study)
    Australian National University
    Open grant
  • 2002 - 2003
    Is autoreactivity to myelin antigens regulated differently in multiple sclerosis and stroke?
    Multiple Sclerosis Research Australia
    Open grant
  • 2001
    Tissue culture equipment for support of studies of T cell apoptosis in multiple sclerosis
    Ramaciotti Foundation
    Open grant
  • 2000 - 2002
    T cell apoptosis in multiple sclerosis and experimental autoimmune encephalomyelitis
    NHMRC Project Grant
    Open grant
  • 1999 - 2001
    Correlation Between Ganglioside-Specific Immune Responses and Disease Prograssion in Multiple Sclerosis
    NHMRC Project Grant
    Open grant
  • 1999
    T Cells and cytokines in inflammatory neuropathy
    Mayne Bequest Fund
    Open grant
  • 1997 - 1998
    Experimental autoimmune encephalomyelitis: clinical, biochemical and anatomical correlations
    National Multiple Sclerosis Society of Australia
    Open grant
  • 1996 - 2020
    Multiple sclerosis clinic
    Multiple Sclerosis Society of Queensland
    Open grant
  • 1996
    Experimental autoimmune encephalomyelitis: clinical, biochemical and anatomical
    Mayne Bequest Fund
    Open grant
  • 1996 - 1998
    Studies of T cell reactivity to myelin antigens in multiple sclerosis
    NHMRC Project Grant
    Open grant
  • 1996 - 2000
    Studies of the mechanisms of relapse of experimental autoimmune encephalomyelitis
    NHMRC Project Grant - 5 Yr Extended with Fellow
    Open grant
  • 1995 - 1997
    Modulation of autoreactive T cell apoptosis in experimental autoimmune encephalomyelitis
    NHMRC Project Grant - Standard
    Open grant

Supervision

Availability

Emeritus Professor Michael Pender is:
Not available for supervision

Supervision history

Completed supervision

Media

Enquiries

For media enquiries about Emeritus Professor Michael Pender's areas of expertise, story ideas and help finding experts, contact our Media team:

communications@uq.edu.au